Aurobindo Pharma

Pharma shares like Aurobindo Pharma, Zydus Lifesciences, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals may rise up to 14 per cent.

Aurobindo Pharma Limited on Thursday said its consolidated net profit for the quarter ended January 31 was down by 18.7 per cent to Rs 491.2 crore against Rs 604.3 crore in Q3FY22. A press release from the drug maker said revenue from operations during the quarter under discussion was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal. Commenting on the company's performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said "We witnessed an improved momentum backed by recovery across our business verticals and our endeavor is to continuously innovate and differentiate." In line with the companys commitment to innovate, there is an increase in the investments in Biosimilars. The company aims to sustain the momentum with new launches, improved cost efficiencies and adherence to the highest standards of compliance, supported by strong execution, he further said. During the quarter, formulation revenue increase by 9.2

Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per cent to 12 per cent.

According to the technical analyst from Anand Rathi, Aurobindo Pharma can rally to Rs 490; while Biocon can jump to Rs 295.

Aurobindo Pharma on Wednesday said its unit has entered into a licensing pact with Evive Biotech to commercialise Ryzneuta in the US market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN). In addition to the US health regulator, Evive's Marketing Authorization Application (MAA), and New Drug Application (NDA) for Ryzneuta are currently under review by European and Chinese regulators. Neutropenia is a common side-effect of chemotherapy and is a condition characterised by low levels of neutrophils, a type of white blood cell that fights infection. The licensing pact has been inked between Evive and Acrotech Biopharma (Acrotech), a New Jersey-based and wholly-owned subsidiary of Aurobindo Pharma USA Inc, Aurobindo Pharma said in a statement. As part of the agreement, Evive will be responsible for the ongoing development, manufacturi

Market participants usually opt for mid-cap or small-cap stocks. But, if one fails to pick the right stock, investment in such stocks can result into huge losses

Aurobindo Pharma's aims to complete its Rs 2,000 crore Penicillin G (Pen G) plant in Andhra Pradesh by March 2024 even as the trial or the pilot batches will take place starting October next year onwards, S Subramanian, Chief Financial Officer, Aurobindo Pharma has said. Replying to a query during the recent earnings call, he said the overall project of USD 235 million, the major will be to put a de-salination plant, the fermentation process, power blocks, among others and multiple subprojects are being done with purchase orders been issued. "So, we believe by next September or October, the installation should be over. After that, the trial or the pilot batches will take place starting October next year onwards. So, our target is to complete the projects by March'24 and it's our endeavour to advance it," Subramanian said. "The material is expected to be received in this quarter and the next quarter and significant portions of the buildings and blocks have been done," he further ...

CLOSING BELL: Among the Sensex 30 shares, Titan, M&M, Maruti, HDFC and Bajaj Finserv were the major per centage losers.

Stocks to watch today: Aurobindo Pharma received EIR from USFDA for its manufacturing facility in Andhra Pradesh; Softbank plans to offload around 29 million shares of Paytm via block deals

Aurobindo Pharma Ltd on Wednesday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facility at Pydibhimavaram in Andhra Pradesh. The company's Unit XI at Pydibhimavaram is an API non-antibiotic manufacturing facility. It was inspected by the US Food and Drug Administration (USFDA) in February 2019 and issued a warning letter in June 2019. It was inspected further by the USFDA from July 25 to August 2, 2022 and issued a Form 483 with three observations. Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. "Subsequent to our responses for the aforesaid observations, we have received an EIR classifying the inspection as Voluntary Action Indicated (VAI) from the USFDA and with this, the inspection at our Unit XI is concluded," Aurobindo Pharma said in a ...

The company said the second quarter performance was subdued mainly due to the macro-environment factors and higher competitive intensity for some products in the US

Aurobindo Pharma on Saturday reported a 41 per cent decline in its consolidated net profit at Rs 409 crore for the second quarter ended September 30, 2022. The Hyderabad-based drug firm had posted a net profit of Rs 697 crore in the July-September period of last fiscal. Revenue from operations also declined to Rs 5,739 crore in the September quarter as against Rs 5,942 crore in the year-ago period. Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company's second quarter performance was subdued, mainly due to macro-environment factors and higher competitive intensity for some products in the US. "However, we are confident that our robust pipeline of new products will provide impetus to the future growth trajectory," he added. Reddy noted that company's continued focus on biosimilars, R&D, innovation and increasing manufacturing capacity will enhance its product offerings in various markets. "We are confident that, the right measures and growth-le

The ED has arrested two company executives linked to liquor trade in the money laundering investigation being conducted by it into the now scrapped Delhi Excise policy case, official sources said Thursday. Benoy Babu of Pernod Ricard and Sharath Reddy of Aurobindo Pharma have been arrested under sections of the Prevention of Money Laundering Act (PMLA), they said. The Enforcement Directorate (ED) has conducted multiple raids in this case so far. In September, it arrested Sameer Mahandru, managing director of a liquor manufacturing company Indospirit. The agency early this month raided the premises of a PA of Delhi Deputy chief minister Manish Sisodia and later questioned him at its office in Delhi. The money laundering case stems from a CBI FIR that had named Sisodia as an accused among others. The CBI had raided the premises of the deputy chief minister and some Delhi government bureaucrats after filing the case. The excise scheme came under the scanner after the Delhi LG recomm

According to reports, ED has arrested Sarath Reddy, director of Aurobindo Pharma, under the money laundering act in the now scrapped Delhi Excise policy case.

Aurobindo Pharma units are recalling different products in the US market for manufacturing lapses, as per the US health regulator. According to the latest Enforcement Report by the US Food and Drug Administration (USFDA), New Jersey-based Aurobindo Pharma USA Inc is recalling 9,504 bottles of Quinapril and Hydrochlorothiazide tablets. The affected lot of the medication, which is used to treat high blood pressure, has been manufactured in India and marketed in the US market by Aurobindo Pharma USA, Inc. As per the USFDA, the company is recalling the affected lot due to "Current good manufacturing practices CGMP deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit." Nitrosamines are a group of compounds which can damage DNA in the long term. The company, a unit of Hyderabad-based Aurobindo Pharma, initiated the Class II voluntary recall on October 5 this year. In a separate statement, USFDA said AuroMedics Pharma LLC, a unit of Aurobindo Phar

Leading drug firms Dr Reddy's Laboratories, Cipla and Aurobindo Pharma are recalling different products in the US market for various issues, according to the US Food and Drug Administration. As per the enforcement report by the US Food and Drug Administration (USFDA), the US-based unit of Dr Reddy's Laboratories is recalling 2,838 ampules of vitamin K deficiency treatment drug Phytonadione Injectable Emulsion. According to the USFDA, Dr Reddy's Laboratories is recalling the affected lot due to "failed stability specifications". "Out of specification results reported at 12-month stability testing for aluminum content," it stated. Dr Reddy's initiated the Class III voluntary recall on September 14 this year. As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences". USFDA further said the US-based arm of domestic drug major Cipla is recalling 9,041 cartons of Arformoterol ..

In the past six months, Aurobindo has underperformed the market by falling 31 per cent, as compared to a marginal 0.07 per cent decline in the S&P BSE Sensex.

CLOSING BELL: ITC, the biggest cigarette maker, and the second largest fast moving consumer goods (FMCG) company in India, regained the market capitalisation of Rs 4 trillion on Friday

Aurobindo Pharma on Thursday said its wholly-owned arm, CuraTeQ Biologics, plans to invest around Rs 300 crore on capacity expansion of biologics manufacturing facilities. The board of directors of CuraTeQ Biologics Pvt Ltd, at its meeting held on Thursday, approved the expansion of its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements, Aurobindo Pharma said in a regulatory filing. "The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore," it said, adding that the facility is likely to be fully operational by FY26. Further, the board also approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities. This would augment the business prospects in this area as the global biologics contract manufacturing demand is growing at 8-10 per cent and CuraTeQ will actively seek customers in CMO area, it added. The compan

Aurobindo Pharma on Monday said the US health regulator has issued one observation after inspecting a plant owned by its US-based unit. The US Food and Drug Administration (USFDA) conducted its Pre-Approval Inspection (PAl) and GMP (Good Manufacturing Practice) inspection from August 22-26 of Raleigh-based plant which has been set up for manufacturing MOl (Metered Dose Inhalers) and derma products, the Hyderabad-based drug firm said in a regulatory filing. The plant is owned by Aurolife Pharma LLC, a wholly-owned step down subsidiary of the company, it added. "At the end of the inspection, Aurolife has been issued a 'Form 483' with 1 observation and the observation is procedural in nature and there are no data integrity issues," Aurobindo Pharma said. The company will respond to the USFDA within the stipulated timeline, it added. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its